Mosaic ImmunoEngineering Inc. announced that two research grants totaling $4.3 million from the National Cancer Institute were awarded to the Company's collaborating scientists and their respective academic institutions. The funding will be used for further studies investigating the activity of CPMV, a first-in-class plant virus used to timulate immune responses against cancer. The Company's lead CPMV oncology candidate, MIE-101, is in late-stage preclinical development.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3131 USD | +0.03% | -22.11% | -47.82% |
Apr. 15 | Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 28 | Mosaic ImmunoEngineering, Inc. Receives Letter of Termination from CWRU | CI |
1st Jan change | Capi. | |
---|---|---|
-47.82% | 2.27M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CPMV Stock
- News Mosaic ImmunoEngineering, Inc.
- Mosaic ImmunoEngineering Inc. Academic Collaborators Receives Grants Totaling $4.3 Million from NCI Focuses on its Novel Immuno-Oncology Platform